Damnacanthal is a potent and selective inhibitor of p56lck tyrosine kinase activity; it inhibits autophosphorylation of p56lck (IC50 = 46 nM) and phosphorylation of exogenous substrates by p56lck (IC50 = 220 nM); it acts as a potent apoptosis-inducing agent with anticancer activity; it exhibits analgesic and anti-inflammatory effects in mice; it shows antifungal activity against Candida albicans; it significantly reduces cell proliferation in a concentration- and time-dependent manner in HCT-116 and SW480 colorectal cancer cells; it induces cell cycle arrest at S/G1 and G2/G1 phases; it increases caspase-3/7 activity and induces apoptosis; it upregulates NAG-1 expression and downregulates cyclin D1 expression; it inhibits colony formation and migration of HCT-116 cells; it demonstrates significant antinociceptive effects in a dose-dependent manner in the formalin test in mice; it significantly inhibits histamine-induced paw edema; it reduces the growth of human lung tumors in vivo without acute toxicity.